|
Eton Pharmaceuticals, Inc (Eton), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced the relaunch of Hemangeol.
“We are excited to deliver another major product launch for the company. Hemangeol is a critical and time-sensitive therapy where early treatment can meaningfully impact outcomes, and the only FDA-approved treatment for infantile hemangiomas. With the integration of Eton Cares and a dedicated rare disease specialty pharmacy model, we are focused on helping patients start therapy quickly and ensuring families are supported from prescription through treatment. Our Hemangeol commercial team has been actively working with caregivers, healthcare professionals, and pharmacies to ensure a seamless transition for patients,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.
“Infantile hemangiomas can evolve rapidly, and timely intervention is critical. In practice, the challenge is often not recognizing when to treat but ensuring that infants can start therapy without delays. Streamlined access to an FDA-approved treatment designed specifically for this population can meaningfully improve both outcomes and the care experience for families,” said Dr. Maria Gnarra Buethe, MD, PhD, Division Chief of Dermatology, Rady Children’s Hospital of Orange County and Director of Pediatric Dermatology, University of California, Irvine.
Dr. Kristi Derrick, MD, ScM, Clinical Assistant Professor, SUNY Downstate Health Sciences University (NY) and Paragon Skin Dermatology (NJ) added, “Infantile hemangiomas are common, but in some cases these skin lesions need to be treated urgently to prevent complications and provide the best cosmetic outcome. When a baby has an infantile hemangioma on the face, scalp, diaper area, skin folds or large or multiple lesions, it is important that the baby can get into a specialist quickly to discuss treatment options.”
“For families, an infantile hemangioma diagnosis is overwhelming and the window of opportunity to potentially prevent negative consequences is narrow. In order to prevent these adverse complications, prompt and early treatment is critical. At the Vascular Birthmarks Foundation, we advocate starting treatment as soon as the lesion is diagnosed. We strongly lobby for all primary care doctors to initiate Hemangeol treatment as soon as medically feasible,” said Dr. Linda Rozell- Shannon, founder & president of The Vascular Birthmarks Foundation, a global non-profit that has networked over 150,000 patients with vascular malformations into treatment for over 30 years.
Hemangeol is an orphan drug indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy. Infantile hemangiomas are non-cancerous vascular tumours which typically appear in the first days or weeks of a newborn’s life. In severe cases, infantile hemangiomas can lead to more serious complications, and require intervention with systemic therapy. Treatment with Hemangeol is typically initiated between five weeks to five months of age, and continues for approximately six months, representing a critical window where timely intervention can prevent complications and improve outcomes. It is estimated that approximately 5,000-10,000 infants are treated with Hemangeol annually in the United States.
Hemangeol (propranolol hydrochloride) oral solution is a prescription medicine used to treat proliferating infantile hemangioma (a type of birthmark) requiring treatment throughout the body.
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently has ten commercial rare disease products: Khindivitm, Increlex, Alkindi Sprinkle, Desmoda, Galzin, Hemangeol, PKU Golike, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The company has four additional product candidates in late-stage development: Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
|